既往有淋病和衣原体等性传播疾病(STD)的病史会增加患前列腺癌的机会,男性中第二常见的恶性肿瘤。然而,导致淋病和衣原体患者前列腺癌发展的分子功能尚不清楚。在这项研究中,我们使用计算生物学方法研究了RNA-seq基因表达谱,以找出潜在的生物标志物,可以帮助我们理解淋病的病理生物学机制,衣原体,和前列腺癌。使用基因表达综合(GEO)数据集的统计方法,发现在这3种疾病中共有22种不同的差异表达基因,其中14种上调(PGRMC1,TSC22D1,SH3BGRL,NNT,CTSC,FRMD3,CCR2,FAM210B,VCL,PTGS1,SLFN11,SLC40A1,PROS1和DSE)和其余8个基因下调(PRNP,HINT3,MARCKSL1,TMED10,SH3KBP1,ENSA,DERL1和KMT2B)。用基因本体论研究这22个独特的失调基因,BioCarta,KEGG,而Reactome揭示了多种改变的分子途径,包括淀粉样蛋白前体蛋白分解代谢过程的调节,铁性凋亡,对人类PPAR途径基因表达的影响,和先天免疫系统R-HSA-168249。四种重要的枢纽蛋白,即VCL,SH3KBP1,PRNP,通过蛋白质-蛋白质相互作用网络分析揭示了PGRMC1。通过分析基因-转录因子和基因-miRNAs的相互作用,还鉴定了显著的转录因子(POU2F2,POU2F1,GATA6和HIVEP1)和转录后调节微小RNA(hsa-miR-7-5p)。在蛋白质-药物相互作用分析中,发现三种潜在的治疗化合物,即INCB3284,CCX915和MLN-1202与上调的蛋白C-C趋化因子受体2型(CCR2)相互作用。拟议的生物标志物和治疗潜在分子可以研究潜在的药理靶点和活性在淋病患者的斗争,衣原体,和前列腺癌。
Having a previous history of sexually transmitted diseases (STDs) such as gonorrhea and chlamydia increases the chance of developing prostate cancer, the second most frequent malignant cancer among men. However, the molecular functions that cause the development of prostate cancer in persons with gonorrhea and chlamydia are yet unknown. In this study, we studied RNA-seq gene expression profiles using computational biology methods to find out potential biomarkers that could help us in understanding the patho-biological mechanisms of gonorrhea, chlamydia, and prostate cancer. Using statistical methods on the Gene Expression Omnibus (GEO) data sets, it was found that a total of 22 distinct differentially expressed genes were shared among these 3 diseases of which 14 were up-regulated (PGRMC1, TSC22D1, SH3BGRL, NNT, CTSC, FRMD3, CCR2, FAM210B, VCL, PTGS1, SLFN11, SLC40A1, PROS1, and DSE) and the remaining 8 genes were down-regulated (PRNP, HINT3, MARCKSL1, TMED10, SH3KBP1, ENSA, DERL1, and KMT2B). Investigation on these 22 unique dysregulated genes using Gene Ontology, BioCarta, KEGG, and Reactome revealed multiple altered molecular pathways, including regulation of amyloid precursor protein catabolic process, ferroptosis, effects on gene expression of Homo sapiens PPAR pathway, and innate immune system R-HSA-168249. Four significant hub proteins namely VCL, SH3KBP1, PRNP, and PGRMC1 were revealed by protein-protein interaction network analysis. By analyzing gene-transcription factors and gene-miRNAs interactions, significant transcription factors (POU2F2, POU2F1, GATA6, and HIVEP1) and posttranscriptional regulator microRNAs (hsa-miR-7-5p) were also identified. Three potential therapeutic compounds namely INCB3284, CCX915, and MLN-1202 were found to interact with up-regulated protein C-C chemokine receptor type 2 (CCR2) in protein-drug interaction analysis. The proposed biomarkers and therapeutic potential molecules could be investigated for potential pharmacological targets and activity in the fight against in patients with gonorrhea, chlamydia, and prostate cancer.